GE HealthCare Launches AI-Powered Prostate Volume Assist for Ultrasound
Featuring automated one-click functionality for capturing prostate volume, the AI-enabled software may help shorten workflows for prostate imaging, biopsies, and ultrasound-guided procedures.
An emerging artificial intelligence software may enable clinicians to quickly obtain automated measurements of prostate volume.
With the launch of Prostate Volume Assist, clinicians can ascertain prostate measurements and calculations with one click, according to GE HealthCare, the manufacturer of the software. The company said the Prostate Volume Assist can be beneficial with prostate imaging and ultrasound-guided procedures.
With the launch of Prostate Volume Assist, clinicians can ascertain prostate measurements and calculations with one click, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)
“Normally, clinicians determine prostate volume through a manual, repetitive process that requires measuring multiple dimensions and applying a mathematical formula,” said Fredrik Gran, head of innovation, surgical visualization and guidance, ultrasound at GE HealthCare. “Prostate Volume Assist uses artificial intelligence to automate this process with a single click, and yield results in less than two seconds. This technology provides an added level of support for (clinicians) to improve efficiencies in the workflow and enable precision care.”
GE HealthCare noted that Prostate Volume Assist will be accessible via the company’s bkActiv, bk3000/5000 and bkSpecto ultrasound modalities.
Recent Videos
Related Content
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Article
Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Article
Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Podcast
Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025Article
In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
